J Virol 86:10857C10861. antibodies realizing distinct epitopes. Delicate but consistent beneficial interactions were observed in some MAb mixtures, whereas less beneficial interactions were observed on a small subset of viruses that are highly sensitive to V3-glycan MAbs. These data demonstrate favorable mixtures of broadly neutralizing HIV-1 MAbs and suggest that such mixtures could have power for HIV-1 prevention and treatment. IMPORTANCE Over the last 5 years, several broadly reactive HIV-1-neutralizing MAbs have been isolated from B cells of HIV-1-infected donors. Each of these MAbs binds to one of the major vulnerable sites (epitopes) on the surface of the viral envelope glycoprotein. Since antibodies to unique viral epitopes could theoretically take action collectively to provide higher potency and breadth of computer virus neutralization, we tested physical mixtures of double, triple, and quadruple mixtures of GSK-3326595 (EPZ015938) neutralizing MAbs focusing on four major epitopes on HIV-1 Env. When tested together, antibody mixtures showed considerably improved neutralization breadth compared to solitary MAbs. This improvement could be explained from the complementary neutralization profiles of individual MAbs. We further shown that every antibody managed its full neutralization potency when used in combination with additional MAbs. These data provide a rationale for medical use of antibody-based mixtures for HIV-1 prevention and therapy. Intro Eliciting broadly neutralizing antibodies through immunization is definitely a major goal of human being immunodeficiency computer virus type 1 (HIV-1) vaccine development. However, vaccine immunogens that can induce such antibodies are not yet available (1,C5). Over the last 5 years, improvements in antigen-specific cell sorting of memory space B cells (6, 7) and improved tradition methods GSK-3326595 (EPZ015938) for solitary B cells (8,C11), together with genetic recovery of antibody variable areas (12, 13), have resulted in the isolation of numerous highly potent and broadly reactive monoclonal antibodies (MAbs) from HIV-1-infected individuals (7,C11, 14,C37). Rabbit Polyclonal to CBR1 Characterization of these antibodies offers uncovered four main sites of vulnerability within the viral envelope glycoprotein spike (Env): the CD4-binding site (CD4bs) (7, 11, GSK-3326595 (EPZ015938) 15,C21, 37), a glycan-dependent site in variable region 3 (V3) of gp120 (9, 14, 22,C25), a variable-region (V1V2) glycan-dependent site within the trimer apex (8, 9, 26,C31), and the membrane-proximal external region (MPER) of gp41 (10, 32,C36). Recently, antibodies to an additional conserved neutralization epitope that bridges gp120 and GSK-3326595 (EPZ015938) gp41 have also been explained (38,C41). The isolation and characterization of these numerous broadly neutralizing MAbs provide templates for rational HIV-1 vaccine design and have facilitated an understanding of the immune pathways leading to the development of broadly neutralizing antibodies (17, 18, 26, 42, 43). In addition to these vaccine implications, GSK-3326595 (EPZ015938) there is the potential for medical use of MAbs by passive transfer for prevention and treatment of HIV-1 contamination. Passive immunization with HIV-1-neutralizing antibodies has provided complete protection against lentiviral contamination in several studies using different animal models, including chimeric simian-human immunodeficiency computer virus (SHIV) challenge of rhesus macaques (44,C50) and HIV-1 challenge of humanized mice (51, 52). Additionally, passive delivery of HIV-1 MAbs has been assessed for efficacy as immunotherapy. Early animal and human studies showed a limited and transient impact on viremia and rapid emergence of neutralization-resistant variants after antibody administration (53,C56). Recently, using the newly isolated MAbs, which are more potent and broadly reactive, several animal studies demonstrated a substantial decrease in plasma viremia as long as antibodies were present, including complete control of viremia in some cases, especially when combinations of MAbs were used (49, 57, 58). The recent resolution of the structure of the native Env trimer (59,C61), together with the crystal structures of liganded MAbs (10, 14, 15, 19,C24, 26,C31, 35, 36, 62), has provided an understanding of the modes of recognition of most major MAbs. These data suggest that, in most cases, MAbs to distinct epitopes should bind the Env trimer without cross-competition. Likewise, binding data have confirmed.
